NASDAQ:CRVS

Corvus Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CRVS

*Your capital is at risk

$11.60

-0.0900 (-0.770%)

At Close: Jun 03, 2026

Corvus Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -41.27. In total, the insiders bought 25.42M and sold 10.9M CRVS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-41.27
● Buy	25.42M shares
● Sell	10.9M shares
90% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence May 18, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -41.27. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (90% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 28, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Thompson Peter A.	Director	15 000 Value: $49.1K
Jan 28, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Thompson Peter A.	Director	15 000 Value: $41.1K
Jan 28, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Thompson Peter A.	Director	15 000 Value: $39.0K
Jan 28, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Thompson Peter A.	Director	15 000 Value: $14.5K
Jan 28, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Thompson Peter A.	Director	15 000 Value: $24.6K
Dec 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Jones William Benton See Remarks	Officer	400 000 Value: $3.52M
Dec 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Miller Richard A Md President And CEO	CEO / President	1 000 000 Value: $8.81M
Dec 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Arcara Jeffrey Chief Business Officer	Officer	100 000 Value: $881.0K
Dec 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Lea Leiv Chief Financial Officer	C-Suite Officer	400 000 Value: $3.52M
Oct 02, 2025 Buy	Stock Option (Right to Buy) A-Award	Moore David Scott Director	Director	30 000 Value: $211.2K
Oct 02, 2025 Buy	Common Stock J-Other	Moore David Scott Insider	Other	0 Value: $0
Oct 02, 2025 Buy	Common Stock J-Other	Moore David Scott Insider	Other	0 Value: $0
Oct 02, 2025 Buy	Stock Option (Right to Buy) A-Award	Moore David Scott Director	Director	30 000 Value: $211.2K
Jun 27, 2025 Buy	Common Stock X-InTheMoney	Orbimed Advisors Llc	Director	1 397 684 Value: $4.89M
Jun 27, 2025 Sell	Common Stock S-Sale	Orbimed Advisors Llc	Director	1 176 332 Value: $4.89M
Jun 27, 2025 Sell	Common Warrants (right to buy) X-InTheMoney	Orbimed Advisors Llc	Director	1 397 684 Value: $4.89M
Jun 27, 2025 Buy	Common Stock X-InTheMoney	Thompson Peter A.	Director	1 397 684 Value: $4.89M
Jun 27, 2025 Sell	Common Stock S-Sale	Thompson Peter A.	Director	1 176 332 Value: $4.89M
Jun 27, 2025 Sell	Common Warrants (right to buy) X-InTheMoney	Thompson Peter A.	Director	1 397 684 Value: $4.89M
Jun 27, 2025 Sell	Common Warrants (right to buy) X-InTheMoney	Thompson Peter A.	Director	1 397 684 Value: $4.89M
Jun 27, 2025 Sell	Common Stock S-Sale	Thompson Peter A.	Director	1 176 332 Value: $4.89M
Jun 27, 2025 Buy	Common Stock X-InTheMoney	Thompson Peter A.	Director	1 397 684 Value: $4.89M
Jun 27, 2025 Sell	Common Warrants (right to buy) X-InTheMoney	Orbimed Advisors Llc	Director	1 397 684 Value: $4.89M
Jun 27, 2025 Sell	Common Stock S-Sale	Orbimed Advisors Llc	Director	1 176 332 Value: $4.89M
Jun 27, 2025 Buy	Common Stock X-InTheMoney	Orbimed Advisors Llc	Director	1 397 684 Value: $4.89M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...

Read Full Profile Here